

Noradrenaline

For use in critical care areas only

Warning – Document uncontrolled when printed

Policy Reference: id1279	Date of Issue: December 2010
Prepared by: Rhona Wilson	Date of Review: December 2012
Lead Reviewer: Rhona Wilson	Version: 1
Authorised by: Policies, Procedures and Guidelines Subgroup of ADTC	Date: June 2011
Distribution <ul style="list-style-type: none"> • A&E Consultants and Nurses • ITU Consultants and Nurses • CCU Consultants and Nurses • MSCU Consultants and Nurses 	
Method E-mail ✓ Paper ✓ Intranet ✓	

Warning – Document uncontrolled when printed

Policy Reference: id1279	Date of Issue: December 2010
Prepared by: Rhona Wilson	Date of Review: December 2012
Lead Reviewer: Rhona Wilson	Version: 1
Authorised by: Policies, Procedures and Guidelines Subgroup of ADTC	Page 1 of 3

Noradrenaline

For use in critical care areas for adults only
Administer via central line only

Strength	For Syringe Pump	For Volumetric pump	Concentration
		Only when infusion rate \geq 5mls/hour (ICU only)	
Single	4mg in 50ml	8mg in 100mls	80micrograms/ml
Double	8mg in 50mls	16mg in 100mls	160micrograms/ml
Triple	12mg in 50mls	24mg in 100mls	240micrograms/ml
Quadruple	16mg in 50mls	32mg in 100mls	320micrograms/ml

Administration

Dilute with glucose 5% and administer via syringe pump. Always start treatment using single strength preparation and titrate to response.

Dose

Titrate dose to achieve clinical target.

If dose is escalating rapidly or if the dose required to reach the desired clinical target exceeds 0.4micrograms/kg/min, the doctor must be contacted to discuss further management. At the consultants discretion

- Another therapy may be started
- sedation level reviewed
- consider using LiDCO (ICU only)
- a new upper limit may be set

To calculate dose in micrograms/kg/min use equation below or use tables overleaf

$$\text{Dose (micrograms/kg/min)} = \frac{\text{Rate (mls/hr)} \times \text{Concentration of noradrenaline in micrograms/ml}}{\text{Bodyweight (kg)} \times 60}$$

Stability

- Syringe should be changed every 24 hours
- Syringe may be made in advance if circumstances require this
- The nurse who has prepared the syringe must administer it
- A syringe should be made up a maximum of 1 hour in advance

Extravasation

Extravasation of noradrenaline may cause local tissue necrosis. Phentolamine can be used for the treatment of extravasation of noradrenaline. 5mg or 10mg of phentolamine in 10mls of sodium chloride 0.9% is injected into the affected area. This is an unlicensed use of phentolamine.

Warning – Document uncontrolled when printed

Policy Reference: id1279	Date of Issue: December 2010
Prepared by: Rhona Wilson	Date of Review: December 2012
Lead Reviewer: Rhona Wilson	Version: 1
Authorised by: Policies, Procedures and Guidelines Subgroup of ADTC	Page 2 of 3

Single Strength Noradrenaline (80micrograms/ml)

Rate mls/hr	Weight (kg) and Dose in micrograms/kg/minute																
	40	45	50	55	60	65	70	75	80	85	90	95	100	105	110	115	120
1	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01
2	0.06	0.06	0.05	0.05	0.04	0.04	0.04	0.04	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.02	0.02
3	0.10	0.09	0.08	0.07	0.06	0.06	0.06	0.05	0.05	0.05	0.04	0.04	0.04	0.04	0.04	0.03	0.03
4	0.13	0.11	0.11	0.10	0.09	0.08	0.08	0.07	0.07	0.06	0.06	0.06	0.05	0.05	0.05	0.05	0.05
5	0.16	0.15	0.13	0.12	0.11	0.10	0.10	0.09	0.08	0.08	0.07	0.07	0.07	0.07	0.06	0.06	0.06
6	0.20	0.17	0.16	0.15	0.13	0.12	0.11	0.11	0.10	0.10	0.09	0.09	0.08	0.08	0.07	0.07	0.07
7	0.23	0.20	0.19	0.17	0.16	0.14	0.13	0.12	0.12	0.11	0.10	0.10	0.09	0.09	0.08	0.08	0.08
8	0.26	0.23	0.21	0.19	0.18	0.16	0.15	0.14	0.13	0.13	0.12	0.11	0.10	0.11	0.10	0.09	0.09
9	0.3	0.27	0.24	0.22	0.20	0.18	0.17	0.16	0.15	0.15	0.13	0.13	0.12	0.11	0.11	0.10	0.10
10	0.33	0.30	0.27	0.24	0.22	0.21	0.19	0.18	0.17	0.16	0.15	0.14	0.13	0.13	0.12	0.12	0.11
11	0.37	0.33	0.29	0.27	0.24	0.23	0.21	0.20	0.18	0.17	0.16	0.15	0.15	0.14	0.13	0.13	0.12
12	0.40	0.36	0.32	0.29	0.27	0.25	0.23	0.21	0.20	0.19	0.18	0.17	0.16	0.15	0.15	0.14	0.13
13	0.43	0.39	0.35	0.32	0.29	0.27	0.25	0.23	0.22	0.20	0.19	0.18	0.17	0.17	0.16	0.15	0.14
14	0.46	0.41	0.37	0.34	0.31	0.29	0.27	0.25	0.24	0.22	0.21	0.20	0.19	0.18	0.17	0.16	0.16
15	0.50	0.44	0.40	0.36	0.33	0.31	0.29	0.27	0.25	0.24	0.22	0.21	0.20	0.19	0.18	0.17	0.17
16	0.53	0.47	0.43	0.39	0.36	0.33	0.30	0.28	0.27	0.25	0.24	0.23	0.21	0.20	0.19	0.19	0.18
17	0.56	0.50	0.45	0.41	0.38	0.35	0.33	0.30	0.28	0.27	0.25	0.24	0.22	0.22	0.21	0.20	0.19
18	0.60	0.53	0.48	0.44	0.40	0.37	0.34	0.32	0.30	0.28	0.27	0.25	0.24	0.23	0.22	0.21	0.20
19	0.63	0.56	0.51	0.46	0.42	0.39	0.36	0.34	0.32	0.30	0.28	0.27	0.25	0.24	0.23	0.22	0.21
20	0.66	0.59	0.53	0.48	0.44	0.41	0.38	0.35	0.33	0.31	0.30	0.28	0.27	0.25	0.24	0.23	0.22

Double Strength Noradrenaline (160micrograms/ml)

Rate mls/hr	Weight (kg) and Dose in micrograms/kg/minute																
	40	45	50	55	60	65	70	75	80	85	90	95	100	105	110	115	120
1	0.07	0.06	0.05	0.05	0.04	0.04	0.04	0.04	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.02	0.02
2	0.13	0.12	0.10	0.10	0.09	0.08	0.08	0.07	0.07	0.06	0.06	0.06	0.05	0.05	0.05	0.05	0.04
3	0.20	0.18	0.16	0.15	0.13	0.12	0.11	0.11	0.10	0.09	0.09	0.08	0.08	0.08	0.07	0.07	0.07
4	0.27	0.24	0.21	0.19	0.18	0.16	0.15	0.14	0.13	0.13	0.12	0.11	0.11	0.10	0.10	0.09	0.09
5	0.33	0.30	0.27	0.24	0.22	0.20	0.19	0.18	0.17	0.16	0.15	0.14	0.13	0.13	0.12	0.12	0.11
6	0.40	0.36	0.32	0.29	0.27	0.25	0.23	0.21	0.20	0.19	0.18	0.17	0.16	0.15	0.15	0.14	0.13
7	0.47	0.41	0.37	0.34	0.31	0.29	0.27	0.25	0.23	0.22	0.21	0.20	0.19	0.18	0.17	0.16	0.16
8	0.53	0.48	0.43	0.39	0.36	0.33	0.30	0.28	0.27	0.25	0.24	0.22	0.21	0.20	0.19	0.19	0.18
9	0.60	0.53	0.48	0.44	0.40	0.37	0.34	0.32	0.30	0.28	0.27	0.25	0.24	0.23	0.22	0.21	0.20
10	0.67	0.59	0.53	0.48	0.44	0.41	0.38	0.36	0.33	0.31	0.30	0.28	0.27	0.25	0.24	0.23	0.22
11	0.73	0.65	0.59	0.53	0.49	0.45	0.42	0.39	0.37	0.35	0.33	0.31	0.29	0.28	0.27	0.26	0.24
12	0.80	0.71	0.64	0.58	0.53	0.49	0.46	0.43	0.40	0.38	0.36	0.34	0.32	0.30	0.29	0.28	0.27
13	0.87	0.77	0.69	0.63	0.58	0.53	0.50	0.46	0.43	0.41	0.39	0.36	0.35	0.33	0.32	0.30	0.29
14	0.93	0.83	0.75	0.68	0.62	0.57	0.53	0.50	0.47	0.44	0.41	0.39	0.37	0.36	0.34	0.32	0.31
15	1.00	0.89	0.80	0.73	0.67	0.61	0.57	0.53	0.50	0.47	0.44	0.42	0.40	0.38	0.36	0.35	0.33
16	1.07	0.95	0.85	0.78	0.71	0.66	0.61	0.59	0.53	0.50	0.47	0.45	0.43	0.41	0.39	0.37	0.36
17	1.13	1.00	0.91	0.82	0.76	0.70	0.65	0.60	0.57	0.53	0.50	0.48	0.45	0.43	0.41	0.39	0.38
18	1.20	1.07	0.96	0.87	0.80	0.74	0.69	0.64	0.60	0.56	0.53	0.50	0.48	0.46	0.44	0.42	0.40
19	1.27	1.13	1.01	0.92	0.84	0.78	0.72	0.68	0.63	0.60	0.56	0.53	0.50	0.48	0.46	0.44	0.42
20	1.33	1.18	1.07	0.97	0.89	0.82	0.76	0.71	0.67	0.63	0.59	0.56	0.53	0.51	0.48	0.46	0.44

Warning – Document uncontrolled when printed

Policy Reference: id1279	Date of Issue: December 2010
Prepared by: Rhona Wilson	Date of Review: December 2012
Lead Reviewer: Rhona Wilson	Version: 1
Authorised by: Policies, Procedures and Guidelines Subgroup of ADTC	Page 3 of 3